Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Skip to main content

Healthcare & Pharmaceuticals

Thailand to narrow gap for AstraZeneca shots in bid to curb Delta variant

2 minute read

A health worker prepares a dose of AstraZeneca COVID-19 vaccine against the coronavirus disease (COVID-19) at the Central Vaccination Center, inside the Bang Sue Grand Station, Thailand, June 21, 2021. REUTERS/Athit Perawongmetha

BANGKOK, June 22 (Reuters) - A Thai medical committee has agreed to narrow the gap between doses of the AstraZeneca (AZN.L) COVID-19 vaccine to eight weeks from 10-12 weeks previously in places where there has been outbreaks of the Delta variant, an official said on Tuesday.

Areas where the more contagious Delta variant, first identified in India, had been detected could "adjust the timing for the second dose," said Kiatiphum Wongrajit, permanent secretary at the public health ministry.

The move comes after Thailand last week abandoned plans for a 16-week gap between AstraZeneca doses in a bid to stretch vaccine supplies to reach more people. read more

Thailand reported the first instance of the Delta variant in Bangkok last month and up to now it has spread to 20 provinces with over 660 cases recorded.

Thailand's vaccination drive, which uses a mix of Sinovac and AstraZeneca shots, faced delays a week after it started in June due to limited supplies. About 2.2 million people are fully vaccinated from a population of over 66 million. read more

Bangkok, the epicentre of the latest outbreak, with around an average of 1,000 new infections per day, has only 20 beds left for coronavirus patients in critical condition at government hospitals in the city, said health official Somsak Akksilp.

Thailand reported 4,059 new infections on Tuesday, bringing the total number of cases to 225,365 and 1,693 fatalities, with more than 85% infections and 95% of deaths coming since April.

Reporting by Chayut Setboonsarng and Panarat Thepgumpanat Editing by Ed Davies

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters